Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacodynamic model of erythropoietin therapy for uremic anemia.

Clinical pharmacology and therapeutics - 1 Jan 1992

Uehlinger D E, Gotch F A, Sheiner L B

Abstract excerpt

Fifty-seven patients receiving chronic high-flux hemodialysis began receiving recombinant alpha-human erythropoietin (rHuEPO). The mean initial rHuEPO dose used in 54 evaluable patients was 9963 +/- 4364 U/week; the final dose was 8972 +/- 4058 U/week. Treatment over a mean period of 154 +/- 40 days (84 to 224 days) resulted in an average increase in hematocrit from 24.7% +/- 3.7% to 32.5% +/- 4.4%. We present a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Dose-Response Relationship, Drug
Share to Erythrocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Genetic Variation

Share to Hematocrit

Share to Recombinant Proteins

Share to Software

Source

Identifiers

PMID: 1732079
DOI: 10.1038/clpt.1992.10

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A pharmacodynamic model of erythropoietin therapy for uremic anemia.PMID 1732079Read ↗

Safety of Roxadustat Combined with Epoetin Alfa in Hemodialysis Patients with Anemia: A Cohort StudySemantic proximity Read ↗

Real World Use of Pegylated Erythropoietin in CKD Anemia: An Indian Modified Delphi ConsensusSemantic proximity Read ↗

Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25 in Hemodialysis Patients: A Prospective, Multicenter, Observational Riona-Oral Iron Absorption TrialSemantic proximity Read ↗

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.Semantic proximity Read ↗

Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4-positive T lymphocytes.Semantic proximity Read ↗

Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.Semantic proximity Read ↗

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.Semantic proximity Read ↗

Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins.Semantic proximity Read ↗

Pharmacokinetics of erythropoietin in genetically anemic mice.Semantic proximity Read ↗

Phenotype, proliferation and apoptosis of B lymphocytes in hemodialysis patients treated with recombinant human erythropoietin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.